Scios Nova Inc. (SCIO)
Stuart Weisbrod of Merrill Lynch lowered his intermediate-term rating to "neutral" from "above average," saying SCIO is fully valued compared to its peer group. Phase II data on Auriculin atrial natriuretic peptide for acute renal failure, to be presented at the November American Society of Nephrology meeting, are provocative but not conclusive